Management of asthma and allergic rhinitis in children during the COVID-19 pandemic Praca przeglądowa
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2020
Słowa kluczowe:
COVID-19, asthma, allergic rhinitis, children
##plugins.themes.bootstrap3.article.main##
Abstrakt
The aim of the study was to present current data on the treatment of children with asthma and allergic rhinitis during the COVID-19 pandemic. To this end, the available literature was reviewed (until 2020, June 1st).
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Emeryk , A., Wawryk-Gawda , E., & Janeczek , K. (2020). Management of asthma and allergic rhinitis in children during the COVID-19 pandemic. Alergoprofil, 16(2), 8-15. https://doi.org/10.24292/01.AP.162300620
Numer
Dział
THERAPY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Pyrć K. SARS-CoV-2. Klinika Nowa. 2020; 27(1): 9-14.
2. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020; 30(7): 1346-51.
3. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012; 4(11): 3044‐68.
4. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020; 39(5): 355‐68.
5. Grzesiowski P. Pandemia COVID-19 – epidemiologia, patofizjologia, aspekty kliniczne. Klinika Nowa. 2020; 27(1): 4-8.
6. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020; 92(7): 747-54. http://doi.org/10.1002/jmv.25807.
7. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6): e20200702.
8. Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663‐5.
9. Gudbjartsson DF, Helgason A, Jonsson H et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020; 382: 2302-15.
10. CDC COVID-19 Response Team. Coronavirus disease 2019 in children – United States, February 12 – April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(14): 422‐6.
11. Cai J, Xu J, Lin D et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020: ciaa198.
12. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. http://doi.org/10.1111/all.14238.
13. Pathak EB, Salemi JL, Sobers N et al. COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract. 2020; 26(4): 325‐33.
14. Tagarro A, Epalza C, Santos M et al. Screening and severity of coronavirus disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA Pediatr. 2020: e201346.
15. Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID- 19) in children. Turk J Med Sci. 2020; 50(SI-1): 592‐603.
16. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. Lancet. 2020; 395(10235): 1481.
17. See KC, Liew SM, Ng DCE et al. COVID-19: four paediatric cases in Malaysia. Int J Infect Dis. 2020; 94: 125‐7.
18. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6): 1088-95.
19. Zheng F, Liao C, Fan QH et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020; 40(2): 275‐80.
20. Streng A, Hartmann K, Armann J et al. COVID-19 in hospitalized children and adolescents. Monatsschr Kinderheilkd. 2020; http://10.1007/s00112-020-00919-7.
21. Xing Y, Ni W, Wu Q et al. Dynamics of faecal SARS-CoV-2 in infected children during the convalescent phase. J Infect. 2020; S0163-4453(20)30177-8.
22. Ong SWX, Tan YK, Chia PY et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020; 323(16): 1610‐12.
23. Ng K, Poon BH, Kiat Puar TH et al. COVID-19 and the risk to health care workers: a case report. Ann Intern Med. 2020; 172(11): 766‐7.
24. Abrams EM, Szefler SJ. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents. J Pediatr. 2020; S0022-3476(20)-30528-X.
25. Zheng XY, Xu YJ, Guan WJ et al. Regional, age and respiratory- secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018; 163(4): 845‐53.
26. Brough HA, Kalayci O, Sediva A et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic. A statement from the EAACI‐section on pediatrics. Pediatr Allergy Immunol. 2020; http://doi.org/10.1111/pai.13262.
27. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; ciaa248.
28. de Lucena TMC, da Silva Santos AF, de Lima BR et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020; 14(4): 597‐600.
29. Chen J, Zhang ZZ, Chen YK et al. The clinical and immunological features of pediatric COVID-19 patients in China. Genes Dis. 2020; http://doi.org/10.1016/j.gendis.2020.03.008.
30. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80(6): 607‐13.
31. Jackson DJ, Busse WW, Bacharier LB et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020; S0091- 6749(20)30551-0.
32. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708‐20.
33. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020, 35(10): e112.
34. Lu X, Xiang Y, Du H et al. SARS-CoV-2 infection in children – understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. 2020. http://doi.org/10.1111/pai.13267.
35. Shaker MS, Oppenheimer J, Grayson M et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020; 8(5): 1477‐88.
36. Kowalski ML, Bartuzi Z, Bręborowicz A et al. Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2 (Position statement of expert panel of the Polish Allergology Society on the management of patients with bronchial asthma and allergic diseases during SARS-CoV-2 pandemics). Alergia Astma Immunologia. 2020; 25(1): 2-7.
37. Samoliński B, Majsiak E, Madej M. Strategia diagnozowania alergii BOTTOM-UP w okresie zagrożenia epidemicznego wirusem SARS-CoV-2 powodującego chorobę COVID-19. Alergia. 2020; 1(83): 16-20.
38. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2019. (Access: 30.05.2020).
39. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2020. (Access: 30.05.2020).
40. Yamaya M, Nishimura H, Nadine L et al. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells. Respir Investig. 2014; 52(4): 251‐60.
41. Yamaya M, Nishimura H, Deng X et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020; 58(3): 155‐68.
42. Abrams EM, Jong GW, Yang CL. Asthma and COVID-19. CMAJ. 2020; 192(20): E551.
43. Levin M, Ansotegui IJ, Bernstein J et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020; 13(5): 100125.
44. Pirożyński M. Terapia wziewna – ze szczególnym uwzględnieniem steroidów – w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
45. Kuna P. Postępowanie u chorych na astmę lub POChP w dobie epidemii COVID-19. Terapia. 2020; numer specjalny 01: 17-21.
46. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015.
47. Doniec Z, Mastalerz-Migas A, Bręborowicz A et al. ReKOMendacje Postępowania w AStmie wczesnodziecięcej dla lekarzy Podstawowej Opieki Zdrowotnej – KOMPAS POZ. Fam Med Prim Care Rev. 2016; 18(2): 181-92.
48. Emeryk A, Pirożyńki M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020 (in press).
49. Dayal D. We urgently need guidelines for managing COVID- 19 in children with comorbidities. Acta Paediatr. 2020. http://doi.org/10.1111/apa.15304.
50. Calvo C, García López-Hortelano M, de Carlos Vicente JC et al. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. An Pediatr (Barc). 2020; 92(4): 241.
51. Shen KL, Yang YH, Jiang RM et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. 2020; 1‐8.
52. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50(SI-1): 611‐9.
53. Dong X, Cao YY, Lu XX et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 00: 1-11.
54. Bousquet J, Akdis C, Jutel M et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020. http://doi.org/ 10.1111/all.14302.
55. Samoliński B, Arcimowicz M. Polskie standardy leczenia nieżytów nosa (PoSLeNN). Alergol Pol. 2013; S1: 1-167.
56. Emeryk A, Rapiejko P. Alergiczny nieżyt nosa. Lekarz POZ. 2019; 5(2): 165-9.
2. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020; 30(7): 1346-51.
3. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012; 4(11): 3044‐68.
4. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020; 39(5): 355‐68.
5. Grzesiowski P. Pandemia COVID-19 – epidemiologia, patofizjologia, aspekty kliniczne. Klinika Nowa. 2020; 27(1): 4-8.
6. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020; 92(7): 747-54. http://doi.org/10.1002/jmv.25807.
7. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6): e20200702.
8. Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663‐5.
9. Gudbjartsson DF, Helgason A, Jonsson H et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020; 382: 2302-15.
10. CDC COVID-19 Response Team. Coronavirus disease 2019 in children – United States, February 12 – April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(14): 422‐6.
11. Cai J, Xu J, Lin D et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020: ciaa198.
12. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. http://doi.org/10.1111/all.14238.
13. Pathak EB, Salemi JL, Sobers N et al. COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract. 2020; 26(4): 325‐33.
14. Tagarro A, Epalza C, Santos M et al. Screening and severity of coronavirus disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA Pediatr. 2020: e201346.
15. Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID- 19) in children. Turk J Med Sci. 2020; 50(SI-1): 592‐603.
16. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. Lancet. 2020; 395(10235): 1481.
17. See KC, Liew SM, Ng DCE et al. COVID-19: four paediatric cases in Malaysia. Int J Infect Dis. 2020; 94: 125‐7.
18. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6): 1088-95.
19. Zheng F, Liao C, Fan QH et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020; 40(2): 275‐80.
20. Streng A, Hartmann K, Armann J et al. COVID-19 in hospitalized children and adolescents. Monatsschr Kinderheilkd. 2020; http://10.1007/s00112-020-00919-7.
21. Xing Y, Ni W, Wu Q et al. Dynamics of faecal SARS-CoV-2 in infected children during the convalescent phase. J Infect. 2020; S0163-4453(20)30177-8.
22. Ong SWX, Tan YK, Chia PY et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020; 323(16): 1610‐12.
23. Ng K, Poon BH, Kiat Puar TH et al. COVID-19 and the risk to health care workers: a case report. Ann Intern Med. 2020; 172(11): 766‐7.
24. Abrams EM, Szefler SJ. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents. J Pediatr. 2020; S0022-3476(20)-30528-X.
25. Zheng XY, Xu YJ, Guan WJ et al. Regional, age and respiratory- secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018; 163(4): 845‐53.
26. Brough HA, Kalayci O, Sediva A et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic. A statement from the EAACI‐section on pediatrics. Pediatr Allergy Immunol. 2020; http://doi.org/10.1111/pai.13262.
27. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; ciaa248.
28. de Lucena TMC, da Silva Santos AF, de Lima BR et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020; 14(4): 597‐600.
29. Chen J, Zhang ZZ, Chen YK et al. The clinical and immunological features of pediatric COVID-19 patients in China. Genes Dis. 2020; http://doi.org/10.1016/j.gendis.2020.03.008.
30. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80(6): 607‐13.
31. Jackson DJ, Busse WW, Bacharier LB et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020; S0091- 6749(20)30551-0.
32. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708‐20.
33. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020, 35(10): e112.
34. Lu X, Xiang Y, Du H et al. SARS-CoV-2 infection in children – understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. 2020. http://doi.org/10.1111/pai.13267.
35. Shaker MS, Oppenheimer J, Grayson M et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020; 8(5): 1477‐88.
36. Kowalski ML, Bartuzi Z, Bręborowicz A et al. Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2 (Position statement of expert panel of the Polish Allergology Society on the management of patients with bronchial asthma and allergic diseases during SARS-CoV-2 pandemics). Alergia Astma Immunologia. 2020; 25(1): 2-7.
37. Samoliński B, Majsiak E, Madej M. Strategia diagnozowania alergii BOTTOM-UP w okresie zagrożenia epidemicznego wirusem SARS-CoV-2 powodującego chorobę COVID-19. Alergia. 2020; 1(83): 16-20.
38. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2019. (Access: 30.05.2020).
39. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2020. (Access: 30.05.2020).
40. Yamaya M, Nishimura H, Nadine L et al. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells. Respir Investig. 2014; 52(4): 251‐60.
41. Yamaya M, Nishimura H, Deng X et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020; 58(3): 155‐68.
42. Abrams EM, Jong GW, Yang CL. Asthma and COVID-19. CMAJ. 2020; 192(20): E551.
43. Levin M, Ansotegui IJ, Bernstein J et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020; 13(5): 100125.
44. Pirożyński M. Terapia wziewna – ze szczególnym uwzględnieniem steroidów – w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
45. Kuna P. Postępowanie u chorych na astmę lub POChP w dobie epidemii COVID-19. Terapia. 2020; numer specjalny 01: 17-21.
46. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015.
47. Doniec Z, Mastalerz-Migas A, Bręborowicz A et al. ReKOMendacje Postępowania w AStmie wczesnodziecięcej dla lekarzy Podstawowej Opieki Zdrowotnej – KOMPAS POZ. Fam Med Prim Care Rev. 2016; 18(2): 181-92.
48. Emeryk A, Pirożyńki M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020 (in press).
49. Dayal D. We urgently need guidelines for managing COVID- 19 in children with comorbidities. Acta Paediatr. 2020. http://doi.org/10.1111/apa.15304.
50. Calvo C, García López-Hortelano M, de Carlos Vicente JC et al. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. An Pediatr (Barc). 2020; 92(4): 241.
51. Shen KL, Yang YH, Jiang RM et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. 2020; 1‐8.
52. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50(SI-1): 611‐9.
53. Dong X, Cao YY, Lu XX et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 00: 1-11.
54. Bousquet J, Akdis C, Jutel M et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020. http://doi.org/ 10.1111/all.14302.
55. Samoliński B, Arcimowicz M. Polskie standardy leczenia nieżytów nosa (PoSLeNN). Alergol Pol. 2013; S1: 1-167.
56. Emeryk A, Rapiejko P. Alergiczny nieżyt nosa. Lekarz POZ. 2019; 5(2): 165-9.